NEAT 001 /ANRS 143 Randomised Trial

 

First line Raltegrivir (RAL) + Darunavir/ Ritonavir (DRV/r) is Non-inferior to Tenofovir/ Emtricitabine (TDF/FTC) + DRV/r

 

Randomised, open label, multicentre, parallel-group, non-inferiority, strategic trial

Phase III

15 countries Austria, Belgium, Denmark, France, Germany, UK, Greece, Hungary, Ireland, Netherlands, Poland, Spain, Sweden

78 sites

Administrative office: NEAT ID Foundation, 27 Old Gloucester Street, London WC1N 3AX, UK

     e: NEAT-ID@NEAT-ID.org     

w: www.NEAT-ID.org

Registered address: PL 709  Rue Haute 322, 1000 Brussels, Belgium

©NEAT ID 2019